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Metformin induces lipid changes on 
sphingolipid species and oxidized 
lipids in polycystic ovary syndrome 
women
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Antonio Hernandez-Mijares2,3,4,6, Reinald pamplona1,6, Victor M. Victor2,5,6* & Mariona Jové1,6*
Metformin is one of the treatments used for pcoS pathology decreasing body weight, plasma 
androgen, FSH and glucose levels. Unfortunately, there is little known about metformin’s effects on 
lipid metabolism, a crucial process in pcoS pathology. We have employed a lipidomic approach to 
explore alterations in the plasma lipid profile of patients with PCOS following metformin treatment. 
The aim is to offer new insights about the effect of metformin in PCOS patients. Plasma samples 
were obtained from 27 subjects prior to and following 12 weeks of metformin treatment. A detailed 
biochemical characterization and lipidomic profile was performed. Metformin reduces BMI, HOMA-IR, 
fSH and androstenedione and increases DHeA-S but no changes were found in glucose levels after 
treatment. Multivariate statistics revealed a specific lipidomic signature due to the effect of 12 weeks 
of metformin treatment in pcoS patients. this signature includes changes in sphingolipid metabolism 
suggesting a crosstalk between these lipid species and the androgenic metabolism and a decrease 
in oxidized lipids reinforcing that metformin treatment improves oxidative stress status. our study 
confirms the specific effect of metformin in lipid metabolism on women with PCOS after 12 weeks of 
treatment.
Polycystic ovary syndrome (PCOS) is a multifactorial disorder that affects 7–9% of women of a reproductive age, 
and is characterized by clinical/biochemical hyperandrogenism, polycystic ovarian morphology (during ultra-
sound) and chronic oligo-anovulation. It is a multifaceted disease in which uncontrolled ovarian steroidogenesis, 
excessive oxidative stress, aberrant insulin signaling, and genetic/environmental factors play a role1. In addition, 
androgen levels are an intrinsic factor2.
PCOS is a pathology specifically associated with insulin resistance (IR) in which both the receptor and the 
mechanism of action of insulin are affected in different target tissues3. Although obesity seems to be heavily 
implicated in the pathogenesis of PCOS, affecting 40–70% of patients4, a considerable proportion of non-obese 
PCOS patients (30%) have IR5. Although the causal factor that leads to IR in PCOS has not been fully deci-
phered, a marked correlation between IR and an inappropriate accumulation of lipid species in insulin target 
tissues have been described. In line with this, there is evidence indicating that lipids act as signalling molecules 
and mediates IR6,7. IR is considered to underlie other aberrations that affect the health of PCOS patients8. For 
example, it influences lipid profile, with 70% of women with PCOS exhibiting at least one abnormal lipid con-
stituent9. Furthermore, female PCOS patients with obesity often have dyslipidaemia, with higher triglyceride 
(TG) levels and lower high-density lipoprotein cholesterol (HDL-C)10 with respect to the healthy population. 
Studies have reported significantly lower levels of HDL-C in PCOS women versus weight-matched controls11. 
Approximately one-third of women with PCOS have been shown to also exhibit metabolic syndrome12. Indeed, 
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PCOS is considered one of the ovarian manifestations of metabolic syndrome13. Alternatively, inflammation may 
also play a crucial role in the development of IR in women with PCOS14,15 and has previously been associated with 
other PCOS associated pathologies, including IR16. In relation to this, previous studies with PCOS patients have 
shown that acute hyperglycemia and IR enhance levels of proinflammatory transcription factor nuclear kappa B 
(NF-kB)17 and those of proinflammatory cytokines17–19.
In addition to hormonal derangements and altered glucose metabolism, PCOS has traditionally been linked 
with atherogenic dyslipidemia, a major determinant of cardiovascular diseases20. However, a recent study per-
formed with PCOS patients without associated pathologies and presenting a non-pathogenic lipid profile (Total 
cholesterol, LDL-C, HDL-C and TG) describes the presence of a PCOS lipidomic fingerprint, in which glycer-
olipid, glycerophospholipid and sphingolipid metabolism is affected21, suggesting that these molecules are related 
to the physiopathology of PCOS and opening up new scenarios in the search for new drugs. Therefore, the lipid 
profile characterized by high triglycerides22, low HDL cholesterol and increased LDL cholesterol, which has been 
related to androgen excess22,23, is a classic profile linked to IR rather than PCOS. Further lipidomic studies that 
analyse 325 lipid species in women with or without PCOS show an association of BMI with 12 classes of lipid spe-
cies including phospholipids, ceramides, gangliosides and acylglycerols, and a free androgen index with 8 classes 
of lipids, namely ceramides, phospholipids and acylglycerols, thus supporting prior findings that adiposity is a 
key driver of dyslipidaemia in PCOS24.
The underlying pathophysiological mechanisms of PCOS are not fully elucidated; consequently current ther-
apeutic options for PCOS women mostly treat symptoms. Metformin is a biguanide used as the first choice oral 
anti-hyperglycemic drug to treat type 2 diabetes. Its mechanism of action is twofold: it promotes a reduction in 
glucose production and it improves insulin sensitivity, the latter being a consequence of changes in lipid metabo-
lism25. The changes arise through the mitochondrial electron transport chain becoming inhibited by metformin 
and the consequent activation of 5′-AMP-activated protein kinase (AMPK), which inhibits fatty acid (FA) syn-
thesis. In this way, metformin prevents lipid storage and the impairment of FA oxidation in insulin-sensitive 
tissues, both of which processes are described in IR26. Recently, metformin has also been used to management 
of hirsutism, acne and IR during PCOS27,28. Concerning IR, metformin exerts multiple actions on different 
insulin-sensitive tissues, including skeletal muscle, adipose tissue, liver, the endothelium and the ovaries29, and 
seems to improve the long-term health of PCOS women by prevent endometrial cancer, diabetes and cardiovas-
cular disease30.
The expanding development of omics approaches has allowed a wider view of the molecular mechanisms 
underlying human pathology. Indeed, we have recently confirmed a specific plasma lipidomic signature in women 
with PCOS with respect to healthy individuals21. This signature implies changes in the metabolism of glycerolip-
ids, glycerophospholipids and sphingolipids, pointing to changes in the glycerophospholipid biosynthetic path-
way and cell signalling. Besides the documented role of metformin in lipid metabolism, the potential lipidomic 
changes in response to metformin treatment in PCOS patients has never been addressed and it would be interest-
ing to determine if metformin can restore the previously reported lipidomic profile that is altered during PCOS21.
The present study aims to clarify whether metformin treatment in PCOS patients induces a specific lipidome 
profile in plasma, thus providing new insight into the management and treatment of this metabolic and endocrine 
disease.
Results
Anthropometric and metabolic parameters. Table 1 shows the anthropometric and metabolic param-
eters of our PCOS patients before treatment (pre-treatment, PRE) and after 12 weeks of metformin (post-treat-
ment, POST). No statistical significance was found when comparing anthropometric parameters between groups 
for all the parameters except weight and BMI, significantly lower after 12-weeks of metformin treatment. Among 
subjects, 11 presented IR (HOMA ≥ 2.6, 2 overweight (BMI ≥ 25) and 12 obesity (BMI ≥ 30) before treatment. 
Parameters related to lipid metabolism (total cholesterol, LDL-c, HDL-c and triglycerides) were also similar in 
PCOS patients after metformin treatment. Glucose and insulin levels showed a trend to decrease after 12-weeks of 
metformin treatment. Although differences in glucose and insulin are not statistically significant, the HOMA-IR 
value is significantly lower after treatment with a reduction of 0.5 points (p < 0.05). We observed that the endo-
crine profile of PCOS subjects changed after 12 weeks of metformin treatment, as represented by decreased FSH 
and androstenedione levels and increased DHEA-S levels (p < 0.05 in all cases).
plasma lipidome of pcoS patients under metformin treatment. In order to assess how 12 weeks of 
metformin treatment effected the global plasma lipidomic profile of PCOS patients, we carried out a non-targeted 
lipidomic approach, focusing on low molecular-weight ionizable lipid molecules (m/z of 300–3000). In the case 
of both polarities (negative and positive), 1950 features were aligned after applying the MFE algorithm31. Then, 
we selected only those features present in at least 50% of the samples of the same group (312 lipid species ionized 
with positive polarity and 64 lipid species in negative polarity).
To determine whether the detected lipidome was altered in the PCOS patients after the 12-week of treatment 
multivariate statistics were applied (Fig. 1 and Fig. S1). All the analyses reflected in Fig. 1 were carried out with 
lipid species ionized with a positive ESI polarity, while the results of the multivariate analyses of lipidome with 
negative ESI are represented in Fig. S1. Non-supervised PCA (Fig. 1A) revealed clustering of both groups, thus 
suggesting that the effect of metformin in PCOS patients has a specific plasma lipidomic signature. In line with 
this, the machine learning algorithm Random Forest correctly classified all of the patients after the treatment 
(classification error PRE: 0.111, classification error POST: 0.000, out of bag error: 0.0556) based on the lipidome 
detected using the positive polarity mode (Fig. 1B). All of the multivariate analyses performed with the negatively 
charged lipid species showed no differences attributable to the metformin treatment in PCOS patients (Fig. S1).
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To better characterize the effect of metformin on the plasma lipidome we performed a parametric paired t-test 
for equal variances. Of the 376 lipid species detected, 45 were found to differ in a statistically significant manner 
between groups. The hierarchical analysis of these 45 lipid species clearly showed a differential regulation after 
and before metformin treatment (Fig. 1C). Interestingly, all of the 18 identified lipid species (based on exact 
mass, retention time, isotopic distribution and/or MS/MS spectrum) were decreased after metformin treatment 
(Table 2), while the remaining 27 were unidentified (Table 3).
Among the lipid species that could be identified, 8 belonged to the glycerophospholipid family, four of which 
(ethanolamine and choline GP-based on) were oxidized and one was a plasmalogen polyunsaturated species. We 
also identified 8 sphingolipids with a differential regulation due to the metformin treatment. Specifically, three 
polyunsaturated ceramides and five sphingomyelins, two of which were monounsaturated and three polyunsatu-
rated. Finally, levels of one oxidized triacylglycerol and one cholesterol ester were also found to be lower after the 
treatment.
In order to further determine to what extent these metabolites can predict the effect of treatment of PCOS 
with metformin, ROC analyses were performed using MS peak areas. The details of the area under the curve, 
as well as the specificity and sensitivity of each lipid species, are presented in Table 2. The lipid species with the 
highest AUC were oxPE(17:3), with a value of 0.90123 and 90% specificity and sensitivity, and SM(d36:6), with 
0.90672 AUC, 90% specificity and 80% sensitivity.
When plasma fatty acid composition was analysed, differences were found due to the effect of the 12-week 
metformin treatment (Table 4). There was a significant increase in the content of 20:2n-6, whereas 20:3n-6, 20:4n-
6, 22:1n-9 and 22:5n-3 were found to have decreased. This led to a slight but significant alteration of the average 
chain length (ACL). When we evaluated other parameters based on fatty acid composition, such as SFA, UFA, 
MUFA, PUFA, PUFAn-3, PUFAn-6, DBI, PI, and AI, no differences were found in PCOS patients after the met-
formin treatment.
Discussion
PCOS is a heterogenic and multigenic metabolic disorder which affects women of a reproductive age and is 
characterized by hyperandrogenism and is commonly associated with other pathologies such as IR and obesity32. 
Currently, there is no universal treatment for PCOS patients, and most available drugs are directed at treating 
symptoms such as androgen excess, IR or oligo-ovulation32,33. Among available insulin-sensitizer drugs, met-
formin is one of the most used, having similar effects as lifestyle changes in terms of decreasing body weight/
BMI and more marked effects in terms of decreasing androgen concentrations34. Furthermore, previous studies 
have demonstrated that metformin reduces plasma glucose levels and FSH in PCOS subjects, and also improves 
the oxidative stress status of patients, among other benefits18. By decreasing gluconeogenesis and lipogenesis and 
enhancing glucose uptake in the liver, skeletal muscle, adipose tissue and ovaries metformin increases insulin 
sensitivity. One potential mechanism proposed for the glucose-lowering effect of metformin is the inhibition of 
PRE POST p-value B.H.
n 27 27
Age (years) 24.7 ± 6.4 —
Weight (kg) 78.9 ± 4.7 76.3 ± 4.4 0.011
BMI (kg/m2) 29.2 ± 1.8 28.2 ± 1.6 0.010
Waist circumference (cm) 94.9 ± 3.8 94.7 ± 3.4 0.882
SBP (mmHg) 119.5 ± 3.3 114.0 ± 3.2 0.100
DBP (mmHg) 73.4 ± 2.8 70.7 ± 2.1 0.220
Total cholesterol (mg/dl) 176.0 ± 5.8 172.1 ± 6.0 0.308
LDL-c (mg/dl) 112.5 ± 4.9 107.6 ± 5.3 0.106
HDL-c (mg/dl) 44.6 ± 2.1 44.7 ± 1.7 0.931
Triglycerides (mg/dl) 94.6 ± 11.6 101.1 ± 12.0 0.242
Glucose (mg/dl) 83.4 ± 1.9 79.5 ± 1.7 0.078
Insulin (μUI/ml) 14.05 ± 1.8 12.42 ± 1.4 0.071
HOMA-IR 2.97 ± 0.4 2.47 ± 0.3 0.034
FSH (mIU/ml) 4.89 ± 0.3 4.06 ± 0.3 0.014
LH (mIU/ml) 7.95 ± 2.3 5.63 ± 0.8 0.302
Free Androgen Index 0.79 ± 0.1 0.72 ± 0.1 0.814
Testosterone (ng/ml) 0.80 ± 0.1 0.73 ± 0.1 0.228
Androstenedione (ng/ml) 4.52 ± 0.4 3.70 ± 0.4 0.013
SHBG (nmol/l) 57.20 ± 8.5 45.25 ± 4.6 0.120
DHEA-S (µg/dl) 293.8 ± 49.8 335.69 ± 57.4 0.027
Table 1. Anthropometric, biochemical and endocrinological data of PCOS patients before treatment with 
metformin (pre-treatment, PRE) and at the end of 12-weeks follow-up (post-treatment, POST). Data are 
expressed as mean ± SEM. Statistical significance (p < 0.05) was considered when compared by a paired t-test 
after Benjamini-Hochberg correction.
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mitochondrial complex I and the consequent stimulation of AMP kinase18,25,34. On the other hand, the intracel-
lular lipid-lowering effects of metformin have been associated with an increase in the mitochondrial channelling 
of fatty acids. Treatment with metformin enhances the mitochondrial β-oxidation process, directing excess intra-
cellular FA towards β-oxidation, which reduces the supply of substrates for the synthesis of bioactive lipids, which 
in turn affects the insulin signalling pathway35. Furthermore, metformin blocks increments in the fatty acid trans-
port protein CD36 and in aberrant ceramide and diacylglycerol content in the skeletal muscle of diabetic rats36. 
However, the molecular mechanisms through which metformin induces these changes are not fully understood. 
As far as we know, the effect of metformin on plasma lipid profile in PCOS has been basically focused on the 
study of lipoprotein profile. Therefore, the objective of this study was to characterize how a 12-week metformin 
treatment affects the plasma lipidomic profile of women with PCOS.
Anthropometric and metabolic parameters in PCOS patients prior to and following 12 weeks of metformin 
treatment showed a decrease in BMI values, whereas no changes in total triglycerides, total cholesterol, LDLc 
and HDLc levels were detected. This reduction in body weight could be partially responsible for the lipidomic 
changes in plasma described after metformin treatment. In terms of insulin resistance parameters, we found a 
slight decrease in plasma glucose and insulin levels after treatment, though these changes were not statistically 
significant. However, the HOMA-IR index decreased after the 12-week treatment, thus indicating an improve-
ment in insulin resistance. These results are in line with most previously published studies on the subject and 
confirm the beneficial effect of metformin on body weight and insulin sensitivity25.
Endocrine measurements revealed several rearrangements after metformin treatment; namely, decreased 
levels of FSH and androstenedione and increased levels of DHEA-S. The FSH levels found in plasma patients 
after treatment were very similar to those detected previously in non-PCOS women, suggesting a reversion 
of PCOS pathology after metformin treatment21. With respect to androstenedione levels, after treatment we 
found very similar levels to those detected in “pure” PCOS women, suggesting that this parameter is affected 
by PCOS-associated pathologies21. Total testosterone concentrations are very much influenced by SHBG 
Figure 1. Multivariate statistics and machine learning show a specific lipidomic signature after 12-weeks 
metformin treatment in PCOS patients. (A) Unsupervised Principal Component Analyses (PCA) and (B) 
Random Forest (RF) classification indicate that it is possible to discriminate PCOS patients before (PRE) 
and after (POST) 12-weeks of metformin basing on their plasma lipidome. (C) Heat map representations of 
hierarchical clustering analyses using 42 most statistical significant lipids species (T-test Paired with Benjamini 
Hochberg Correction) between PCOS patients before and after 12-weeks metformin treatment. Unknown 
identities are represented as exact mass_ retention time. Metabolite identification is based on exact mass, 
retention time, isotopic distribution and/or MSMS spectrum. Each line of this graphic represents an accurate 
mass ordered by retention time, coloured by its abundance intensity normalized to internal standard and 
baselining to median/mean across the samples. The scale from −6 (blue) to 6 (red) represents this normalized 
abundance in arbitrary units. All the analyses have been performed with the 312 features detected and filtered in 
ESI positive polarity.









ROC Specificity Sensitivity m/z RT Adduct
GL
OxTAG(37:0)b −1.06 3.05E-02 down 0.68724 0.7 0.7 700.6212 9.89 M + NH4+
OxPE(17:3)b −1.40 5.85E-05 down 0.90123 0.9 0.9 536.1593 7.44 M + H+
PA(33:0)a −1.08 1.70E-03 down 0.79012 0.9 0.6 663.4474 7.97 M + H+
PS(28:0)a −1.04 4.74E-02 down 0.72702 0.7 0.7 680.4734 7.96 M + H+
GP
OxPC(43:2)b −1.19 2.01E-03 down 0.71605 0.9 0.6 758.5637 7.63 M + H+
OxPC(36:4)b −41.39 1.99E-02 down 0.71811 0.9 0.5 812.5046 3.06 M + H+
PI(38:4)c −43.45 3.09E-02 down 0.71331 0.8 0.6 887.5621 6.35 M + H+
PE(P-38:6)c −54.66 4.47E-02 down 0.70096 0.9 0.6 746.5292 8.23 M + H+
OxPE(21:5)b −1.17 4.70E-02 down 0.83676 0.7 0.9 610.1774 7.93 M + Na+
Cer(d34:2)a −99.43 4.48E-03 down 0.74623 0.8 0.7 536.4794 6.05 M + H+
Cer(d39:7)a −1.12 3.48E-02 down 0.72291 0.9 0.6 596.5207 8.28 M + H+
Cer(d41:3)a −1.19 1.23E-02 down 0.8107 0.7 0.8 632.591 8.27 M + H+
SP
SM(d32:1)c −65.34 2.32E-02 down 0.76818 0.7 0.7 675.5355 6.41 M + H+
SM(d34:3)a −1.12 1.65E-04 down 0.84088 0.9 0.7 699.5899 9.16 M + H+
SM(d34:1)a −1.54 8.25E-04 down 0.83813 0.9 0.7 703.5677 7.24 M + H+
SM(d36:6)a −1.08 8.69E-05 down 0.90672 0.9 0.8 721.5014 7.97 M + H+
SM(d38:2)c −1.06 1.16E-02 down 0.77778 0.9 0.7 757.6426 9.17 M + H+
ST CE(16:0)a −35.61 4.98E-02 down 0.738 0.8 0.7 642.6079 10.77 M + NH4+
Table 2. Identified compounds statistically different between groups (paired t-test with Benjamini Hochberg 
correction). aLipid species identified by exact mass and retention time and MS/MS spectrum. bLipid species 
identified by exact mass and retention time and confirmed with LipidMatch libraries. cLipid species with a 
possible identity based on exact mass and retention time.
Compound FC p (BH Corr)
Change post 
treatment mass RT ESI
307.3267_3.11 −1.22 1.70E-03 down 307.3267 3.11 POS
329.1986_2.74 −83.21 4.47E-02 down 329.1986 2.74 NEG
353.2763_0.87 33,497.97 2.03E-11 up 353.2763 0.87 POS
353.2783_1.35 4,901.52 6.69E-07 up 353.2783 1.35 POS
371.3094_5.12 201.58 9.70E-03 up 371.3094 5.12 POS
428.3618_5.09 258.04 2.93E-02 up 428.3618 5.09 POS
448.3312_5.02 −1.27 3.69E-04 down 448.3312 5.02 POS
504.3942_6.49 −1.09 9.70E-03 down 504.3942 6.49 POS
555.353_2.75 −210.03 1.01E-02 down 555.353 2.75 NEG
567.6994_7.39 −1.18 1.51E-02 down 567.6994 7.39 POS
588.5232_8.48 506.49 2.13E-03 up 588.5232 8.48 POS
612.5996_9.41 −1.15 9.70E-03 down 612.5996 9.41 POS
625.7527_7.39 −1.24 2.41E-03 down 625.7527 7.4 POS
701.2067_5.37 −32.21 4.45E-02 down 701.2067 5.37 POS
816.4542_3.06 −27.2 3.32E-02 down 816.4542 3.06 POS
856.8275_10.44 −1.16 8.16E-03 down 856.8275 10.44 POS
909.7012_6.46 62.93 1.96E-02 up 909.7012 6.46 POS
938.6609_7.98 −48.1 1.23E-02 down 938.6609 7.98 POS
1023.2967_9.4 −36.31 3.89E-02 down 1023.2967 9.4 POS
1054.8875_10.21 −1.09 3.32E-02 down 1054.8875 10.21 POS
1156.3756_7.4 −98.37 2.04E-02 down 1156.3756 7.4 POS
1169.0574_8.25 −1.31 2.13E-03 down 1169.0574 8.25 POS
1193.8123_7.29 −1.14 1.44E-02 down 1193.8123 7.29 POS
1198.768_7.29 −1.16 3.16E-03 down 1198.768 7.29 POS
1198.8363_7.9 32.52 1.16E-02 up 1198.8363 7.9 POS
1270.441_9.65 −234.77 3.97E-03 down 1270.441 9.65 POS
1464.4113_10.18 −1.41 5.74E-03 down 1464.4113 10.18 POS
Table 3. Unidentified compounds statistically different between groups (Paired t-test with Benjamini Hochberg 
correction). NEG: negative ESI mode; POS: positive ESI mode. Compounds are represented as exactmass_
retentiontime.
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concentration, as 65% of plasma testosterone is bound to SHBG37. Previous studies in PCOS patients without 
associated pathologies showed no changes in SHBG and testosterone levels compared with control subjects, thus 
reinforcing the idea that PCOS-associated pathologies could be partially responsible for the changes observed in 
androgenic metabolism21. In the present study, we did not observe differences in testosterone and SHBG levels 
after metformin treatment.
Once we characterized the classical parameters of PCOS patients, we analyzed the whole plasma lipidomic 
profile using an LC-MS-based technique. Furthermore, fatty acid composition was also measured in order to bet-
ter characterize the composition of the plasma lipidome. The results revealed the existence of a plasma lipidomic 
profile specifically associated with a 12-week metformin treatment in PCOS patients, which is the first time this 
has been reported. This signature is defined mostly by glycerophospholipids and sphingolipids; we detected 45 
lipid molecular species whose concentration was altered by the effect of metformin treatment (7 lipid species were 
up-regulated, while 38 were down-regulated).
The interaction between sphingolipids and steroid hormones has previously been described, and this interac-
tion modulates the steroidogenic signaling pathway. Specifically, these lipids can modulate steroidogenesis, acting 
at different levels as a second messengers, paracrine/autocrine regulators and/or ligands for nuclear receptors38. 
For example, ceramides have been shown to regulate progesterone and testosterone production, although the 





C14:0 0.668 ± 0.007 0.725 ± 0.009 0.23
C16:0 22.475 ± 0.06 22.614 ± 0.054 0.701
C16:1(n-7) 1.505 ± 0.019 1.456 ± 0.017 0.533
C18:0 8.103 ± 0.032 8.119 ± 0.044 0.927
C18:1(n-9) 20.948 ± 0.125 21.203 ± 0.137 0.641
C18:1(n-7) 1.647 ± 0.007 1.597 ± 0.006 0.257
C18:2(n-6) 31.644 ± 0.148 32.242 ± 0.177 0.497
C18:3(n-3) 0.285 ± 0.003 0.324 ± 0.005 0.169
C18:4(n-3) 0.144 ± 0.001 0.152 ± 0.001 0.11
C20:0 0.149 ± 0.001 0.182 ± 0.004 0.127
C20:1(n-9) 0.222 ± 0.002 0.237 ± 0.004 0.56
C20:2(n-6) 0.034 ± 0 0.054 ± 0.002 0.042
C20:3(n-6) 1.615 ± 0.015 1.472 ± 0.013 0.015
C20:4(n-6) 5.976 ± 0.046 5.597 ± 0.044 0.006
C20:5(n-3) 0.04 ± 0.001 0.048 ± 0.001 0.067
C22:0 0.253 ± 0.002 0.26 ± 0.002 0.505
C22:1(n-9) 2.074 ± 0.035 1.605 ± 0.019 0.003
C22:4(n-6) 0.177 ± 0.001 0.171 ± 0.001 0.077
C22:5(n-6) 0.143 ± 0.003 0.116 ± 0.001 0.114
C22:5(n-3) 0.251 ± 0.002 0.212 ± 0.002 0.002
C24:0 0.111 ± 0.002 0.099 ± 0.001 0.384
C22:6(n-3) 1.226 ± 0.016 1.176 ± 0.013 0.427
C24:1(n-9) 0.268 ± 0.002 0.262 ± 0.002 0.514
C26:0 0.039 ± 0.001 0.076 ± 0.006 0.286
ACL 17.845 ± 0.004 17.811 ± 0.003 0.012
SFA 31.798 ± 0.067 32.075 ± 0.071 0.527
UFA 68.202 ± 0.067 67.925 ± 0.071 0.527
MUFA 26.665 ± 0.133 26.36 ± 0.141 0.639
PUFA 41.537 ± 0.149 41.565 ± 0.176 0.974
PUFA(n-3) 1.947 ± 0.015 1.912 ± 0.015 0.586
PUFA(n-6) 39.59 ± 0.141 39.653 ± 0.175 0.941
DBI 130.443 ± 0.263 128.959 ± 0.278 0.282
PI 73.754 ± 0.31 71.893 ± 0.287 0.138
AI 48.762 ± 0.304 49.009 ± 0.31 0.862
Ratio MUFA/SFA 0.841 ± 0.005 0.822 ± 0.004 0.394
Table 4. Total fatty acid composition of plasma from subjects at the baseline and at the end of 12-weeks 
follow-up. Abbreviations: ACL, average chain length; SFA, saturated fatty acids; UFA, unsaturated fatty acids; 
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; PUFAn-3, polyunsaturated fatty acids 
series n-3; PUFAn-6, polyunsaturated fatty acids series n-6; DBI, double bond index; PI, peroxidizability index; 
AI, anti-inflammatory index.
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In the present work, we described lower levels of 3 ceramides and 4 sphingomyelins after metformin treat-
ment, suggesting that the effect of metformin on androgenic metabolism is partially mediated by sphingolipid 
metabolism regulation. Moreover, the role of sphingolipids, and specially ceramides, in the mediation of insulin 
resistance40–42 has been reported previously, so the effect of metformin on parameters of insulin resistance in 
women with PCOS could also be a result of the interaction of these species with the insulin signaling pathway.
Concerning glycerophospholipids, we identified 8 species that were down-regulated after metformin treat-
ment, 4 of which were oxidized. Surprisingly, we also identified an oxidized TAG. The effect of metformin on cell 
redox status has been described previously18. The present results reaffirm the improvement of oxidative stress in 
PCOS patients after metformin treatment and reveal that an improvement also takes place in the lipid metabo-
lism, thus decreasing lipoxidative damage.
Globally, fatty acid analyses indicated minor changes in fatty acid composition after metformin treatment. 
Although we observed changes in C20-based polyunsaturated fatty acids (C20:2 (n-6), C20:2 (n-6), C20:6 (n-6)), 
C22:1 (n-9) and C22:5(n-3), the variations only represented about 0.2% of ACL reduction, while no changes were 
detected in the other parameters calculated. The present results may indicate a modulation of elongase and desat-
urase activity, especially in the elongases ELOVL3, 5 and 2 and desaturases Δ8 and 543. Fatty acid elongation and 
desaturation are crucial processes in the biosynthesis of saturated, monounsaturated and polyunsaturated fatty 
acids. Furthermore, the deregulation of these enzymes’ activity has been previously related to IR and diabetes44,45. 
Specifically, previous studies in mice have reported a relationship between low ELOVL5 activity in the liver and 
glucose intolerance and insulin resistance46,47. In line with this, our results suggest that the minor alterations 
found in some PUFA could have been a response to slight changes in insulin levels and insulin sensitivity induced 
by metformin.
The principle limitation of the present study is the number of patients (n = 27) and the fact that they came 
from a reduced geographical area. Furthermore, we have used the Rotterdam criteria for this study, and not the 
last international guideline, due to the fact that our patients were part of a previously recruited cohort. Moreover, 
as we have stated before, the PCOS condition is usually associated with other pathologies, such as IR or obesity. 
In the present study we included 11 IR patients and 6 non-IR patients, and so we cannot be sure that IR was not a 
cofounding factor. Further studies with a larger cohort would guarantee a “purer” PCOS population. In addition 
to these population and clinical factors, our study has not enabled us to unravel the biological significance of this 
compositional complexity. Moreover, although sampling was scheduled to minimize the potential influence of 
diet on the lipidome, we cannot rule out the possibility that some compounds appearing as a result of the metab-
olism of nutrients affected the plasma lipidome in general, although the fact that our cohort was from a small 
geographic area would suggest that they were relatively homogeneous in terms of lifestyle and dietary habits.
All in all, we can conclude that metformin treatment induces a specific plasma lipidomic profile in PCOS 
women that is characterized mainly by a decrease in sphingolipids and glycerophospholipids and a reduction of 
lipoxidative species. We believe that this work could aid future research in the exploration of the molecular mech-
anisms involved in sphingolipid – steroid interaction. Our study confirms that lipid profile highlights a specific 
effect of metformin on PCOS women after 12 weeks of treatment.
Methods
Subjects. This study was carried out in the Service of Endocrinology at the University Hospital Dr. Peset 
(Valencia, Spain). Plasma samples of twenty-seven women with PCOS before and after treatment for 12 weeks 
with metformin were analysed. Following the criterion of our Hospital and according to a previous study pub-
lished18 treatment with metformin was initiated at 500 mg per day (during the first 2 weeks). After 2 weeks it was 
increased to 1000 mg/day (weeks 3 and 4) and then to 1500 mg/d during weeks 5–12. Patients did not take any 
other medication.
Diagnosis of PCOS was confirmed using the Rotterdam criteria48. In brief, presence of oligoovulation (cycles 
longer than 35 days or less than 26 days)49; free testosterone levels higher than 0.5 ng/dl (this cut-off level was 
estimated as the mean ± 2 SD according to the levels in healthy women); hirsutism (Ferriman-Gallwey score > 7) 
and polycystic ovaries (presence of at least 12 small −2 to 9 mm- follicles in each ovary), assessed by trans-vaginal 
ultrasonography. Ultrasound scans were performed and scored independently by one of two experienced and 
blinded reviewers.
None of the subjects had any condition affecting her reproductive physiology or any systemic or endocrine 
disease or galactorrhea. Exclusion criteria were malignant neoplasia, active infectious diseases, anemia, diabe-
tes mellitus, history of ischaemic heart disease, thromboembolism, stroke and the taking of antihypertensive or 
lipid-lowering drugs. It was confirmed for all participants the absence of any medication that might have affected 
the hypothalamic-pituitary-gonadal axis during the previous semester. Approval by the ethics committee of the 
University Hospital Dr. Peset was obtained and the study was performed in accordance with the declaration of 
Helsinki. All participants provided their informed consent as required by these institutions.
Biochemical determinations. All participants were subject to an anthropometric evaluation to measure 
weight (kg), height (m) and waist circumference (cm) and to calculate the body mass index (BMI = weight (kg)/
height (m)2). The weight was determined without footwear and with light clothing using electronic scales with 
an approximation of 0.1 kg and a capacity of up to 200 kg. The height was measured with a stadiometer with an 
approximation of 0.5 cm. The BMI was calculated by dividing the weight in kilograms by the square of the height 
in metres. The circumference of the waist was measured at the natural indentation between the 10th rib and the 
iliac crest and the circumference of the hips at the height of the major trochanter, using a metric tape with approx-
imations of 0.5 cm. All measurements were made by the same nurse-study. Blood was collected from the antecubi-
tal vein on the follicular phase of the menstrual cycle or after 3 months of amenorrhea; after 12 hours of fasting. To 
separate serum and plasma from blood cells, samples were immediately centrifuged at 1500 g for 10 min at 4 _C. 
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Fresh samples were used to measure biochemical parameters and the remaining aliquots were stored at −80 °C 
for subsequent measurement of lipidomic parameters.
Total cholesterol and triglycerides were measured using enzymatic assays (Beckman Coulter, La Brea, CA, 
USA). High density lipoprotein cholesterol (HDLc) levels were obtained by a direct method using a Beckman 
LX-20 autoanalyser (Beckman Coulter, La Brea, CA, USA). The intraserial variation coefficient was < 3.5% for all 
determinations. Levels of low density lipoprotein cholesterol (LDLc) were calculated using the Friedewald for-
mula50. Insulin concentration was determined by means of an enzymatic luminescence technique. Glucose levels 
were obtained with a Dax-72 autoanalyzer using enzymatic techniques (Bayer Diagnostic, Tarrytown, NY, USA). 
The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using baseline glucose and 
insulin levels:51 HOMA = (fasting insulin (μU/ml) × fasting glucose (mmol/L)/22.5. Concentration of high sen-
sitivity C-reactive protein (hsCRP) was assessed by an immunonephelometric assay (Behring Nephelometer II, 
Dade Behring, Inc., Newark, DE, USA) which had an intra-assay coefficient of variation of 8.7% and a sensitivity 
of 0.01 mg/L. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were measured using a 2-site 
monoclonal non-isotopic system (Architect, Abbott Laboratories, Abbott Park, IL). Androstenedione, testoster-
one and sex hormone binding globulin (SHBG) were measured in our hospital’s Clinical Analysis Service using 
specialized chemiluminiscence techniques.
Differences among anthropometric and metabolic parameters were analyzed by paired paired t-test for equal 
variances (p < 0.05 with Benjamini- Hochberg Multiple Testing Correction) and differences were considered 
significant when p < 0.05).
Lipidomic analysis. Chemicals. Synthetic lipids were from Avanti Polar Lipids Inc. (Alabaster, AL, USA) 
and Sigma-Aldrich (Madrid, Spain). Fatty acid methyl ester standards were from Larodan Fine Chemicals 
(Mälmo, Sweden) and from Sigma-Aldrich (Madrid, Spain). Methyl tert-butyl ether (MTBE) LC-MS, acetonitrile 
LC-MS, isopropanol LC-MS, potassium chloride, chloroform, ammonium formate and ammonium hydroxide 
were purchased from Sigma-Aldrich (Madrid, Spain); methanol was from Carlo Erba (Milano, Italy); acetone 
was from Riedel-de-Häen (Seelze, Germany); and LC/MS-grade isopropanol and formic acid were from Baker 
(Phillipsburg, NJ, USA).
Untargeted lipidomic analysis: Global lipidomic profile. Preparation of lipid standards. For external 
and internal standardization lipid standards consisting of labeled lipids (see Supplementary Table 1) were used. 
Stock solutions were prepared by dissolving lipid standards in MTBE at a concentration of 1 mg/mL and working 
solutions were diluted to 2.5 μg/ mL in MTBE.
Lipid extraction. A lipidomic analysis was performed to the plasma sample based on a previously validated 
method52. Briefly, to precipitate the protein fraction, 5 μl of miliQ water and 20 μl of methanol were added to 
10 μl of plasma sample. After the addition, samples were shaken for 2 min. Then, 250 μl of MTBE plus internal 
standards were added and samples were ultra-sounded in a water bath (ATU Ultrasonidos, Valencia, Spain) with 
a frequency and power of 40 kHz and 100 W, respectively, at 10 °C for 30 min. Then, 75 μL of miliQ water were 
added to the mixture and organic phase was separated by centrifugation (1,400 g) at 10 °C for 10 min. The upper 
phase, containing all the extracted lipid species, was collected and subjected to mass-spectrometry. A pool of all 
lipid extracts was prepared and used as quality controls (QC) as previously described53.
LC-MS/MS method. Lipid extracts were subjected to liquid chromatography coupled to mass-spectrometry 
(LC-MS) using an Agilent UPLC 1290 coupled to the Q-TOF MS/MS 6520 (Agilent Technologies, Barcelona, 
Spain) basing on previously published method54. Sample compartment was refrigerated at 4 °C and, for each 
sample, 10 μl of lipid extract was applied onto 1.8 μm particle 100 × 2.1 mm id Waters Acquity HSS T3 column 
(Waters, Mildord, MA, USA) heated at 55 °C. The flow rate was 400 μl/min with solvent A composed of 10 mM 
ammonium acetate in acetonitrile-water (40:60, v/v) and solvent B composed of 10 mM ammonium acetate in 
acetonitrile-isopropanol (10:90, v/v). The gradient started at 40% B and reached 100% B in 10 min and held for 
2 min. Finally, the system was switched back to 60% B and equilibrated for 3 min. Duplicate runs of the samples 
were performed to collect positive and negative electrospray ionized lipid species in a TOF mode, operated in 
full-scan mode at 100 to 3000 m/z in an extended dynamic range (2 GHz), using N2 as nebulizer gas (5 L/min, 
350 °C). The capillary voltage was set 3500 V with a scan rate of 1 scan/s. Continuous infusion using a double 
spray with masses 121.050873, 922.009798 (positive ion mode) and 119.036320, 966.000725 (negative ion mode) 
was used for in-run calibration of the mass spectrometer. For MS/MS analyses, we applied a previously described 
method55.
Data analyses. The MassHunter Data Analysis Software (Agilent Technologies, Barcelona, Spain) was used to 
collect the results and the MassHunter Qualitative Analysis Software (Agilent Technologies, Barcelona, Spain) to 
obtain the molecular features of the samples, representing different, co-migrating ionic species of a given molec-
ular entity (i.e. ion adducts) using the Molecular Feature Extractor algorithm (Agilent Technologies, Barcelona, 
Spain)31. We selected samples with a minimum absolute abundance of 5000 counts and with a minimum of 2 ions. 
Compounds from different samples were aligned using a RT window of 0.1% ± 0.15 min and a mass window of 
10.0 ppm ± 2.0 mDa. Only common features (found in at least 50% of the samples of the same condition) were 
analyzed, correcting for individual bias and excluding possible contaminants and artefacts. Finally, MassHunter 
Mass Profiler Professional Software (Agilent Technologies, Barcelona, Spain) was used to perform a non-targeted 
lipidomic analysis over the extracted features. Only common features (found in at least 50% of the samples of 
the same condition) were taken into account to correct for individual bias. Multivariate statistics (Hierarchical 
Clustering, PCA and Random Forest analyses) and biomarker analysis were done using both MassHunter Mass 
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Profiler Professional and Metaboanalyst softwares56,57. The masses representing significant differences by the 
paired t-test for equal variances (p < 0.05 with Benjamini- Hochberg Multiple Testing Correction) were searched 
against the LIPID MAPS database (exact mass ppm < 20) and identified with the R-based tool LipidMatch58. 
Finally, the MS/MS spectra were checked using the LipidBlast software59.
targeted Lipidomic analysis: plasma fatty acids composition. Fatty acid preparation. After lipid 
extraction, fatty acyl groups were analyzed as methyl esters derivatives by gas chromatography (GC)55. Briefly, 
fatty acids were transesterified by incubation in 2 ml of 5% methanolic HCl at 75 °C for 90 min. The resulting fatty 
acid methyl esters (FAMEs) were extracted by adding 2 ml of n-pentane and 1 ml of saturated NaCl solution. The 
n-pentane phase was separated, evaporated under N2 gas, re-dissolved in 80 μl of carbon disulfide and 2 μl were 
used for GC analysis.
GC method. The analysis was performed on a GC System 7890A with a Series Injector 7683B and a flame ion-
ization detector (FID) (Agilent Technologies Inc., Barcelona, Spain) equipped with a DBWAX capillary column 
(length 30 m × inner diameter 0.25 mm × film thickness 0.20 μm; Agilent Technologies Inc., Barcelona, Spain). 
The injections were performed in the splitless mode. The temperature of the injector was 220 °C. The flow rate of 
helium (99.99%) carrier gas was maintained at a constant rate of 1.8 ml/min. The column temperature was held at 
145 °C for 5 min; subsequently, the column temperature was increased by 2 °C/min to 245 °C for 50 min, and held 
at 245 °C for 10 min, and with a post-run of 250 °C for 10 min.
Data analysis. Identification of the twenty-four FAMEs was made by comparison with authentic standards. 
Results were expressed as mol%. The fatty acid profile detected, identified and quantified represents more than 
95% of the total chromatogram. The following fatty acid indexes were calculated: saturated fatty acids (SFA); 
unsaturated fatty acids (UFA); monounsaturated fatty acids (MUFA); polyunsaturated fatty acids (PUFA) from 
n-3 and n-6 series (PUFAn-3 and PUFAn-6); average chain length (ACL) = [(Σ%Total14 × 14) + (Σ%Total16 
× 16) + (Σ%Total18 × 18) + (Σ%Total20 × 20) + (Σ%Total22 × 22) + (Σ%Total24 × 24)]/100]; double bond 
index (DBI) = [(1 × Σmol% monoenoic) + (2 × Σmol% dienoic) + (3 × Σmol% trienoic) + (4 × Σmol% tetrae-
noic) + (5 × Σmol% pentaenoic) + (6 × Σmol% hexaenoic)]; peroxidizability index (PI) = [(0.025 × Σmol% 
monoenoic) + (1 × Σmol% dienoic) + (2 × Σmol% trienoic) + (4 × Σmol% tetraenoic) + (6 × Σmol% pen-
taenoic) + (8 × Σmol% hexaenoic)]; and anti-inflammatory index (AI): [[(20:3n-6) + (20:5n-3) + (22:6n-3)]/ 
(20:4n-6)] * 100. Comparisons between groups were analyzed with a paired t-test for equal variances. The level of 
statistical significance was set at p < 0.05 in all the analyses.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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